WO2005058162A1 - 医療用針および医療用デバイス - Google Patents
医療用針および医療用デバイス Download PDFInfo
- Publication number
- WO2005058162A1 WO2005058162A1 PCT/JP2004/018781 JP2004018781W WO2005058162A1 WO 2005058162 A1 WO2005058162 A1 WO 2005058162A1 JP 2004018781 W JP2004018781 W JP 2004018781W WO 2005058162 A1 WO2005058162 A1 WO 2005058162A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medical needle
- cross
- sectional area
- section
- lancet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/14—Devices for taking samples of blood ; Measuring characteristics of blood in vivo, e.g. gas concentration within the blood, pH-value of blood
- A61B5/1405—Devices for taking blood samples
- A61B5/1411—Devices for taking blood samples by percutaneous method, e.g. by lancet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/158—Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/150022—Source of blood for capillary blood or interstitial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150053—Details for enhanced collection of blood or interstitial fluid at the sample site, e.g. by applying compression, heat, vibration, ultrasound, suction or vacuum to tissue; for reduction of pain or discomfort; Skin piercing elements, e.g. blades, needles, lancets or canulas, with adjustable piercing speed
- A61B5/150061—Means for enhancing collection
- A61B5/150099—Means for enhancing collection by negative pressure, other than vacuum extraction into a syringe by pulling on the piston rod or into pre-evacuated tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150053—Details for enhanced collection of blood or interstitial fluid at the sample site, e.g. by applying compression, heat, vibration, ultrasound, suction or vacuum to tissue; for reduction of pain or discomfort; Skin piercing elements, e.g. blades, needles, lancets or canulas, with adjustable piercing speed
- A61B5/150106—Means for reducing pain or discomfort applied before puncturing; desensitising the skin at the location where body is to be pierced
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150229—Pumps for assisting the blood sampling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150274—Manufacture or production processes or steps for blood sampling devices
- A61B5/150282—Manufacture or production processes or steps for blood sampling devices for piercing elements, e.g. blade, lancet, canula, needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150389—Hollow piercing elements, e.g. canulas, needles, for piercing the skin
- A61B5/150396—Specific tip design, e.g. for improved penetration characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150389—Hollow piercing elements, e.g. canulas, needles, for piercing the skin
- A61B5/150404—Specific design of proximal end
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150412—Pointed piercing elements, e.g. needles, lancets for piercing the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150412—Pointed piercing elements, e.g. needles, lancets for piercing the skin
- A61B5/150419—Pointed piercing elements, e.g. needles, lancets for piercing the skin comprising means for capillary action
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150412—Pointed piercing elements, e.g. needles, lancets for piercing the skin
- A61B5/150427—Specific tip design, e.g. for improved penetration characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150442—Blade-like piercing elements, e.g. blades, cutters, knives, for cutting the skin
- A61B5/150458—Specific blade design, e.g. for improved cutting and penetration characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150503—Single-ended needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150503—Single-ended needles
- A61B5/150511—Details of construction of shaft
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3286—Needle tip design, e.g. for improved penetration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
- A61M5/422—Desensitising skin
Definitions
- the present invention relates to a medical needle such as a lancet and an injection needle, and a medical device using the same, and more particularly to a medical needle made of a biocompatible material and a medical device using the same.
- Patent Document 1 JP-A-10-57490
- a lancet that is punctured at an appropriate body part to collect a small amount of blood also minimizes physical stress, that is, cuts out as few cell tissues as possible, It is preferable to infiltrate into the cell tissues so that other cell tissues are divided.
- a minimally invasive medical needle needle and lancet
- one aspect of the present invention aims to provide a minimally invasive medical needle that minimizes pain (burden) given to a patient.
- a first aspect of the present invention is a medical needle which extends in a predetermined direction and whose cross-sectional area of a vertical cross section cut by a plane perpendicular to the predetermined direction regularly increases and decreases depending on a distance from a distal end portion.
- At least one passage extending in a predetermined direction is internally formed, and the passage includes at least one opening.
- the medical needle has a holding portion connected to the rear end portion, and the holding portion has at least one chamber communicating with the passage.
- it has at least one groove extending in a predetermined direction.
- the medical needle has a holding portion connected to the rear end portion, and the holding portion has at least one chamber communicating with the groove.
- the cross-sectional area of the vertical cross section is between the adjacent maximum point and minimum point, linear or Increase or decrease in a curve.
- the vertical cross section has a triangular, square, hexagonal, polygonal, circular, or elliptical shape.
- the cross-sectional area of the vertical cross section at each local maximum point gradually decreases from the front end to the rear end.
- the cross-sectional area of the vertical cross section at each minimum point gradually increases from the front end to the rear end.
- cross-sectional area of the vertical cross section at the minimum point closest to the rear end is smaller than the cross-sectional area of the vertical cross section at each of the other minimum points.
- the distance between a pair of adjacent maximum points is substantially the same.
- the distance between a pair of adjacent maximum points may be gradually reduced from the front end toward the rear end.
- the medical needle further has a diffraction grating.
- the tip has a radius of curvature of 10 / m or less.
- the medical needle has a slit extending in a predetermined direction.
- the medical needle is made of a biocompatible material, and is more preferably integrally formed using a biodegradable material.
- a medical needle made of a biodegradable material and extending in a predetermined direction, wherein the medical needle is cut when cut in a plane perpendicular to the predetermined direction.
- a first enlarged region having a triangular cross-section having a cross-sectional area that varies depending on the distance of the force at the distal end, and being continuously formed integrally along a predetermined direction, the cross-sectional area monotonically increasing; It has a reduced area in which the product monotonically decreases and a second enlarged area in which the cross-sectional area monotonically increases, and the maximum cross-section giving the maximum cross-sectional area in the first and second enlarged areas has substantially the same shape and cross-sectional area. It is characterized by having.
- the medical needle has at least one additional reduced region having a monotonically decreasing cross-sectional area and at least one additional reduced region having a monotonically increasing cross-sectional area, which is continuously formed integrally in a predetermined direction. And an additional enlarged area.
- the minimum cross-section that gives the minimum cross-sectional area in the reduced area is substantially equal to the maximum cross-section. It has a typical similar shape and is about 1/4 or more of the maximum cross-sectional area. More preferably, the cross-sectional area of the smallest cross section is about 4/9 or more of the cross-sectional area of the largest cross section. Further, the distance between the maximum cross sections in the first and second enlarged regions is about 1 ⁇ m or more.
- the cross-sectional areas of the first and second enlarged regions increase linearly with the first and second increasing ratios, respectively, and the first increasing ratio is approximately equal to the second increasing ratio. 1Z 16 times or more, 1 time or less. More preferably, the first increase ratio is about 1/9 of the second increase ratio
- the medical needle further includes a holding portion connected to a rear end of the medical needle, which is a biodegradable material.
- the medical needle has at least one passage extending in a predetermined direction inside the medical needle.
- the holder has at least one chamber communicating with the passage.
- the passage has at least one opening.
- the passage has at least two openings spaced by a predetermined distance.
- the medical needle has a plurality of passages, and the holder has a plurality of chambers individually communicating with the passages.
- the medical needle has at least one groove extending in a predetermined direction therein.
- the medical needle further includes a plurality of vertical holes that extend in a direction perpendicular to the predetermined direction and accommodates the medicine, and a sealing portion made of a biodegradable material that seals the vertical holes.
- the thickness of the sealing portion in the direction perpendicular to the predetermined direction differs depending on the arrangement position of each vertical hole.
- a medical needle made of a biodegradable material and extending in a predetermined direction, wherein the medical needle is cut when cut in a plane perpendicular to the predetermined direction. It has a trapezoidal cross-section with a base that varies depending on the distance of the tip force, and is formed continuously and integrally in a predetermined direction, with a first enlarged area where the base monotonically increases and a base monotonically decreasing. A reduced area and a second enlarged area whose base is monotonically increased, and a maximum cross-section providing the largest base in the first and second enlarged areas has substantially the same shape and base. Is a special feature.
- the medical needle has at least one additional reduced region whose base is monotonically reduced and at least one additional reduced region whose base is monotonically increased, which are continuously formed integrally in a predetermined direction. And an enlarged area.
- the minimum cross section that gives the minimum base in the reduced area is about 1Z2 or more of the base of the maximum cross section. More preferably, the base of the minimum cross section is about 2 ⁇ 3 or more of the base of the maximum cross section. Further, the distance between the maximum cross sections in the first and second enlarged regions is about 1 ⁇ m or more. Further, it is preferable that a continuous curved surface is formed between the reduced area and the second enlarged area to continuously connect them.
- a certain area in which a trapezoidal cross section cut along an arbitrary plane perpendicular to a predetermined direction gives a substantially constant length base is formed between the reduced area and the second enlarged area. It is molded in one piece.
- the bases of the first and second enlarged regions increase linearly at the first and second increasing ratios, respectively, and the first increasing ratio is approximately equal to the second increasing ratio. More than 1/4 times and less than 1 time. More preferably, the first increase ratio is about 1/3 times the second increase ratio.
- the medical needle further includes a holding portion connected to a rear end of the medical needle, which is a biodegradable material.
- a medical medical device in which a cross-sectional area of a vertical cross section extending in a predetermined direction and cut along a plane perpendicular to the predetermined direction regularly increases and decreases depending on a distance from a distal end portion.
- a medical device including a needle, the medical needle having a plurality of local maximum points at which the cross-sectional area of the vertical cross section is maximum, and a plurality of local points at which the cross-sectional area of the vertical cross section is minimum.
- the cross-sectional area of the vertical section at the local maximum point closest to the tip is the same as or larger than the cross-sectional area of the vertical section at each of the other local maximum points.
- the pain given to the patient can be reduced as much as possible, and the damage at the puncture site of the patient can be suppressed as much as possible.
- FIG. 1 is a perspective view of a lancet according to a first embodiment of the present invention.
- FIG. 2 (a) to FIG. 2 (c) are a front view, a side view, and a plan view of the lancet shown in FIG. 1, respectively.
- FIG. 3 is a perspective view of another lancet of the first embodiment.
- 4 (a) to 4 (c) are a front view, a side view, and a plan view of the lancet shown in FIG. 3, respectively.
- FIGS. 5 (a) to 5 (c) are a perspective view, a side view, and a plan view of another lancet of the first embodiment, respectively.
- FIG. 6 is a perspective view of a lancet according to a second embodiment of the present invention.
- FIG. 7 (a) to FIG. 7 (c) are a front view, a side view, and a plan view of the lancet shown in FIG. 5, respectively.
- FIG. 8 is a perspective view of another lancet of the second embodiment.
- FIGS. 9 (a) to 9 (c) are a front view, a side view, and a plan view of the lancet shown in FIG. 8, respectively.
- FIGS. 10 (a) to 10 (c) are a perspective view, a side view, and a plan view of a lancet according to a third embodiment of the present invention.
- FIGS. 11 (a) to 11 (c) are a side view, a plan view, and a rear view, respectively, of the lancet of the first modification.
- FIG. 12 (a) and FIG. 12 (b) are a side view and a bottom view of another lancet of Modification Example 1, respectively.
- FIG. 13 (a) and FIG. 13 (b) are a side view and a plan view, respectively, of still another lancet of the first modification.
- FIG. 14 (a) and FIG. 14 (b) are a side view and a bottom view of a lancet of Modification Example 2, respectively.
- FIG. 15 (a) and FIG. 15 (b) are side views of another lancet of the second modification.
- FIG. 16 (a) and FIG. 16 (b) are perspective views of a lancet according to a fourth embodiment of the present invention.
- FIG. 17 (a) to FIG. 17 (c) are a front view, a side view, and a plan view of the lancet shown in FIG. 16 (a).
- FIG. 18 (a) to FIG. 18 (c) are a front view, a side view, and a plan view of the lancet shown in FIG. 16 (b).
- FIG. 19 (a) to FIG. 19 (d) are a perspective view, a front view, a side view, and a plan view of a lancet according to a fifth embodiment of the present invention.
- FIG. 20 (a) and FIG. 20 (b) are a side view and a plan view of an alternative lancet of the fifth embodiment.
- FIG. 21 (a) to FIG. 21 (c) are a front view, a side view, and a plan view of a lancet according to a third modification of the fifth embodiment.
- FIG. 22 (a) to FIG. 22 (c) are a front view, a side view, and a plan view of a lancet according to a modification 4 of the fifth embodiment.
- FIG. 23 (a) to FIG. 23 (c) are a front view, a side view, and a plan view of a lancet according to a fifth modification of the fifth embodiment.
- FIG. 24 (a) to FIG. 24 (c) are a front view, a side view, and a plan view of a lancet according to a modification 6 of the fifth embodiment.
- FIG. 25 is a plan view of a lancet according to Embodiment 6 of the present invention.
- FIG. 26 is a plan view of a lancet according to a modification 7 of the sixth embodiment.
- FIG. 27 is a plan view of a lancet according to a modification 8 of the sixth embodiment.
- FIGS. 28A to 28C are a bottom view, a side sectional view, and a sectional view enlarging a part of a diffraction grating of a lancet according to Modification 9 of the above embodiment.
- FIGS. 29A and 29B are plan views of a lancet according to Modification 10 of the above embodiment.
- FIGS. 30 (a) to 30 (c) are a front view, a side view, and a plan view of a lancet according to a modification 11 of the embodiment.
- FIGS. 31 (a) to 31 (c) are a front view, a side view, and a plan view of a lancet according to Modification 12 of the above embodiment.
- lancet 1 Using lancet 1, a small amount of blood is collected, for example, by puncturing an appropriate body part (eg, a fingertip) of a diabetic patient for blood glucose measurement.
- an appropriate body part eg, a fingertip
- the lancet 1 extends in the X direction and has a triangular cross section when cut along an arbitrary plane.
- the base, height, and cross-sectional area of the triangular cross section vary depending on the distance from the tip 11 or the position in the X direction.
- the lancet 1 has a first enlarged area (cell incision area) 10 in which the cross-sectional area monotonically increases, a reduced area (frictional force relaxation area) 20 in which the cross-sectional area monotonically decreases, and a monotonous cross-sectional area again.
- a second enlarged area (cell incision area) 30 that increases. Further, the holding section 40 is connected to the second enlarged area 30.
- the lancet 1 of the present invention extends in a predetermined direction (X direction) as shown in FIG.
- the cross-sectional area of the cross section (vertical cross section) cut in a plane perpendicular to this (the Y-Z plane) increases and decreases regularly depending on the distance of the tip 11 force.
- the lancet 1 has a plurality of local maximum points (Y-Z planes 51 and 53) where the cross-sectional area of the vertical cross section is maximum, and a local minimum point (Y-Z plane 52) where the cross-sectional area of the vertical cross section is minimum. It is designed so that the cross-sectional area of the vertical section at the maximum point 51 closest to the tip is the same as the cross-sectional area of the vertical section at each of the other maximum points 53.
- the lancet 1 of the present invention is generally composed of any biocompatible material including a polymer, a biopolymer, a protein, and a biocompatible inorganic material.
- Examples of the high molecular polymer include, but are not limited to, polychlorinated vinyl, polyethylene glycolone, parylene, polyethylene, polypropylene, silicone, polyisoprene, polymethyl methacrylate, fluororesin, polyetherimide, and polyethylene.
- biopolymers include cellulose, starch, chitin 'chitosan, agar, carrageenan, alginic acid, agarose, burlan, mannan, curdlan, xanthan gum, dielan gum, pectin, xyloglucan, guar gum, and lignin.
- Oligosaccharides here It contains luronic acid, schizophyllan, lentinan, etc., and proteins include collagen, gelatin, keratin, fibrous mouth, glue, sericin, vegetable protein, milk protein, orchid protein, synthetic protein, heparin, and nucleic acid.
- Sugar, candy, glucose, maltose, sucrose, and polymer alloys thereof can also be used.
- biocompatible inorganic materials include ceramics, nanocomposite ceramics, A1O / ZrO composite ceramics, SiN-based nanocomposite materials, hydroxyapatite, and calcium carbonate.
- the lancet 1 of the present invention is a biodegradable polymer containing, for example, polylactic acid, polydalicholic acid, polycaprolactone, collagen, starch, hyanoleronic acid, alginic acid, chitin, chitosan, cellulose, gelatin and the like. , And a biodegradable material composed of these compounds.
- lancet 1 formed by using a biodegradable material such as polylactic acid is subjected to an upright treatment, it is suitably decomposed into water and carbon dioxide by microorganisms in the soil. That is, when the lancet 1 of the present invention is formed using a biodegradable material, a part of the lancet that is not only environmentally friendly than when formed using another biocompatible material is partially lost and remains in the body. Even in this case, it is also easily biodegraded in the body in the same way, so that a very safe lancet can be realized.
- a biodegradable material such as polylactic acid
- the first and second enlarged areas 10 and 30 and the reduced area 20 have a partial external shape of a predetermined quadrangular pyramid.
- This quadrangular pyramid has a predetermined height (H) in the front view of FIG. 2 (a) and the side view of FIG. 2 (b), and has a predetermined length in the plan view of FIG. 2 (c).
- the surface is an equilateral triangle.
- the first enlarged area 10 of the lancet 1 has an outer shape obtained by cutting a quadrangular pyramid on a Y-Z plane 51 passing through a first diagonal, and is reduced in size.
- the region 20 has an outer shape obtained by cutting a quadrangular pyramid by a YZ plane 51 passing through a first diagonal line and a plane 52 parallel to the YZ plane 51.
- the second enlarged region 30 has an outer shape obtained by cutting another quadrangular pyramid by a Y-Z plane 53 passing through the first diagonal and a plane 52 parallel to the first diagonal.
- the first enlarged area 10 the reduced area 20, and the second enlarged area 30 are such that the second diagonal of each pyramid is on the same straight line, and the bottom of each pyramid is on the same plane. It is integrally molded so as to be arranged at
- the lancet 1 configured as described above has a triangular cross section when cut along an arbitrary YZ plane, and the base, height, and cross sectional area of the lancet 1 Increases or decreases linearly depending on the distance of or the position in the X direction.
- the base and the height of the cross section cut along an arbitrary YZ plane linearly increase or decrease using the distance from the tip as a parameter.
- the force can be defined as any function that is monotonically increasing or monotonically decreasing, such as a quadratic function, which can increase or decrease in a curve. That is, the base, the height, and the cross-sectional area of the triangular cross section in each of the regions 10, 20, and 30 are given by a linear or non-linear function using the position in the X direction as a parameter.
- the maximum cross-section (cross-section cut along the YZ planes 51 and 53) giving the maximum cross-sectional area in the first and second enlarged regions 10 and 30 ) are substantially congruent with one another, have substantially the same triangular shape and size, and provide the smallest cross-sectional area in the reduced area 20 (cross-section cut along the YZ plane 52) and It has a similar shape.
- the lancet 1 of the first embodiment has at least one additional reduced region 20a, 20b and 20 which are also integrally formed continuously along the X direction.
- Yo And enlarged areas 30a and 30b The largest cross-section giving the largest cross-sectional area in each of the enlarged regions 10, 30 likewise has substantially the same shape and size.
- the lancet 1 When the lancet 1 configured as described above invades cellular tissue (in the skin or muscle) in the body, as shown in FIGS. 1 and 3, the lancet 1 has a first enlarged area (cell incision area) 10. Three sides (ridges) 15a, 15b, and 16 of the quadrangular pyramid make incision of peripheral cells with the tip 11 as a fulcrum. The cells invade into the tissue by pushing them apart. At this time, the frictional force generated between the bottom surface 14 and the pair of side surfaces 17a, 17b and the peripheral cells is very large, and the peripheral cells can be strongly drawn deep by the frictional force with the penetration of the lancet 1 into the body. .
- lancet 1 of the present invention when the first enlarged area 10 enters the body and then proceeds further into the body, the cross-sectional area in the reduced area (frictional force reducing area) 20 decreases. Therefore, the frictional force generated between the reduced area 20 and the surrounding tissue is substantially reduced, and the surrounding cells return to their original normal positions by their own elasticity. Therefore, the peripheral cell force pulled on the first enlarged region 10 returns to the original position, and the physical stress applied thereto is cancelled.
- lancet 1 is only half (L / 2) the length of the second diagonal of the pyramid
- peripheral cells that have been pulled deeper into the depths are released from the frictional force and return to their normal positions without being torn apart, substantially reducing pain to the patient and covering a wide area. It is possible to prevent irreparable damage to peripheral cells.
- the three sides (ridges) 35a, 35b, which constitute the second enlarged area (cell incision area) 30 as in the first enlarged area 10 36 incises the peripheral cells, and the bottom surface and the pair of side surfaces 37a and 37b push the uncut cells so as to spread into the cell tissue.
- the largest cross-sections giving the largest cross-sectional area in the first and second enlarged regions 10 and 30 are substantially congruent and have substantially the same shape and dimensions, It is possible to avoid incision of peripheral cells more than necessary for the lancet 1 to enter the body.
- the process by which the lancet 1 of the present invention invades the body includes the steps of incising peripheral cells in each of the enlarged areas 10 and 30, and invading other cells by force, and the steps of invading each of the reduced areas 20 and the surrounding area. Step of relaxing the frictional force with the cells and returning the surrounding cells to their original position This is realized by repeating.
- the pain given to the patient is substantially alleviated by returning the peripheral cells in a wide area to the original positions.
- the size of the peripheral cells depends on the body part where the lancet 1 is punctured, but is usually about 10 zm, and in the case of microcells such as capillaries, about.
- the lengths (L 1, L 2) of the first and second diagonals 12, 13 of the pyramid are preferably about 85 to about 180 ⁇ m.
- the height (H) of the quadrangular pyramid is preferably in the range of about 42.5 to about 90 zm. That is, the largest cross-section giving the largest cross-sectional area in the first enlarged region 10 has a triangular shape having a base of about 85 to about 180 ⁇ m and a height of about 42.5 to about 90 ⁇ m
- the strength between the reduced region 20 and the second enlarged region 30 is markedly reduced, and it is very easy to break. That is, when the bottom and the height of the minimum cross section are about 42.5 to about 90 / im and about 21/2 to about 45 ⁇ , respectively, the lancet 1 is easily broken.
- the base and the height of the minimum cross section in the reduction region 20 are set to be about 1/2 or more of the base and the height of the maximum cross section, that is, the cross-sectional area force of the minimum cross section It is designed to be about 1/4 (square of 1/2) or more of the cross-sectional area of the maximum cross section in each enlarged area 30. More preferably, the base and height of the minimum cross section are about 2/3 or more of the base and height of the maximum cross section, that is, the cross-sectional area of the minimum cross section is It is designed to be more than about 4/9 (2/3 square) of the cross-sectional area. As described above, according to the present invention, it is possible to provide a highly reliable lancet 1 that can be reliably penetrated into the body so as to be easily broken.
- the reduced region 20 reduces or reduces the frictional force between the first enlarged region 10 and the cell, and requires at least the size of a cell.
- the distance (D) between the maximum cross sections in the enlarged areas 10 and 30 of 2, that is, the distance between the Y-Z planes 51 and 53 is designed to be at least 1 ⁇ m, preferably 5 ⁇ m.
- the side surface 21 of the reduction region 20 and the side surface 37 of the second enlargement region 30 are substantially flat, and both cross each other. As a result, an acute angle portion (discontinuous portion) is formed.
- the lancet 1 may have a continuous curved surface 58 that continuously connects the side surface 21 and the side surface 37 as shown in FIG. As a result, the lancet 1 can be hardly broken due to stress concentrated at a discontinuous portion between the side surfaces 21 and 37.
- the holding portion 40 connected to the second enlarged region 30 is illustrated as having a triangular prism shape, but may be a quadrangular prism.
- the lancet 2 of the second embodiment will be described in detail with reference to FIGS.
- the lancet 2 of the second embodiment has the same configuration as the lancet 1 of the first embodiment except that it has a fixed area (reinforcement area) integrally formed between the reduced area and the second enlarged area. The description of the points to be performed is omitted.
- a triangular prism having substantially the same Y and Z dimensions ly and lz as the minimum cross-section at 20 has a bottom surface 61 and a triangular prism outer shape having a height in the X direction lx, and has a reduced area 20 and a second enlarged area. It is provided to reinforce the strength between the regions 30.
- the constant region 60 has a substantially identical triangular cross-section with a base of ly and a height of lz when it is cut in any YZ plane.
- the base and the height ly, lz of the cross section of the constant area 60 are preferably adjusted to the enlarged areas 10, 30.
- the base and height L, H of the maximum cross-section of at least half (ly ⁇ L / 2, lz ⁇ H / 2), more preferably at least 2Z3 (ly ⁇ 2L / 3, lz ⁇ 2H / 3) It is configured as follows.
- the lancet 2 of Embodiment 2 has at least one additional piece that is similarly continuously formed along the X direction as shown in Figs. 8 and 9. ⁇ 20a, 20b, 3 ⁇ 460a, 60b, and 3 ⁇ 4: ⁇ : 30a, 30b.
- the lancet 3 of the third embodiment will be described in detail with reference to FIG.
- the lancet 3 of the third embodiment is the same as the lancet 1 of the first embodiment except that the tip 11 of the first enlarged area 10 is designed to be sharper than that of the lancet 1 of the first embodiment. Therefore, the description of the overlapping points will be omitted.
- the height and the base length of the cross section of the second enlarged region 30 cut along the YZ plane are linearly expressed by a gradient (increase ratio) indicated by a chain line 54.
- the height of the cross section and the length of the base in the first enlarged region 10 are designed to increase linearly with a gradient (increase ratio) indicated by a solid line 55.
- the ratio (k) in which the height and the length of the base of the cross section in the first enlarged region 10 shown by the solid line 55 increase (k) changes from the gradient (k) shown by one dotted line 56 to the gradient shown by the other dotted line 57. Change (k) in the range (k ⁇ k
- the slope (k) of one dotted line 56 of the first enlarged region 10 is equal to that of the second enlarged region 30.
- the gradient shown by the dotted line 54 is the same as the gradient (k), while the gradient shown by the dotted line 57 is
- the increase rate (K) of the cross-sectional area of the cross section in the first enlarged area 10 is about 1/16 times (1/1) the increase rate (K) of the cross-sectional area of the cross section in the second enlarged area 30. 4 squared)
- ⁇ ⁇ / 3).
- ⁇ ⁇ / 3
- the lengths of the first and second diagonals (L 1, L 2) of the quadrangular pyramid are the same and the height is
- the length is in the range of L / 2 to 2L, preferably in the range of 3L / 2, and the ridge angle ⁇ ⁇ ⁇ ⁇ at the front end 11 shown in FIG. 10 (a) is in the range of about 14 ° to 45 °. , Preferably about 18.3 °.
- the height of the cross section and the length of the base in the first enlarged region 10 of the lancet 3 of the third embodiment are designed to increase more gradually than in the second enlarged region 30. Therefore, the tip 11 of the first enlarged region 10 is sharper than in the first embodiment. Therefore, the lancet 3 of Embodiment 3 can penetrate the tissue more easily and cause less pain to the patient. The ability to do S.
- the lancet 101 of the first modification of the first to third embodiments will be described in detail with reference to FIG. 11 to FIG.
- the lancet 101 of the first modification has the same configuration as that of the lancets of the first to third embodiments except that the lancet 101 has a passage and a chamber therein. Therefore, the description of the same points will be omitted.
- the lancet 101 of the first modification has at least one passage 71 extending in the X direction so as to penetrate through the inside of each of the enlarged regions 10 and 30 and each of the reduced regions 20.
- the holding portion 40 has a square pillar-shaped cross section when cut along an arbitrary YZ plane, At least one chamber 81 communicating with the passage 71 is formed.
- at least one opening 72 is provided, for example, on the bottom surface 73 of the reduced area 20 in FIG.
- the opening 72 may have any shape, but is preferably formed in a circular shape having a diameter of 10 ⁇ or less so that red blood cells, white blood cells, and the like do not enter the passage 71.
- a pair of electrodes (not shown) spaced apart from each other are arranged in the passage 71 configured as described above, and a micro chemical analysis system (/ iTAS: Micro Total Analysis System) or the like is installed in the chamber 81.
- a biosensor (not shown) is arranged. According to the lancet 101 configured as described above, when punctured into the body, the serum component entering through the opening 72 can be immediately and easily analyzed by the microchemical analysis system.
- the lancet 101 of the first modification can also be used as an injection needle. That is, by connecting a micropump (not shown) to the chamber 81 and creating a negative pressure in the chamber 81 after the lancet 101 is punctured into the body, blood can be easily collected.
- a lancet 101 is provided as shown in FIG.
- a groove 74 extending in the X direction may be provided on the bottom surface 73.
- a desired blood component can be analyzed.
- the lancet 101 of the first modification has a plurality of (two in FIG. 13) passages 75 and 76 extending in the X direction, as shown in FIG.
- a plurality of chambers 82 and 83 are formed in 40 and individually communicate with the passages 75 and 76.
- a plurality of openings 77a-77c, 78a 78c communicating with the passages 75, 76 are formed, for example, in FIG. 13 by the first enlarged area 10, the reduced area 20, and the second Formed on the side of the enlarged area 30.
- each of the openings 77 and 78 can be sealed with a sheet (not shown) made of the same biodegradable material, and punctured into the body, and then can be gradually released after a lapse of a predetermined time. Further, the thickness of the sheet sealing each opening 77, 78 can be changed by the passages 75, 76 to control the timing at which the drug sealed in each chamber 82, 83 is gradually released. .
- the adjacent openings 77, 78 are spaced apart by a predetermined distance.
- the distance between the electrodes is accurately determined, so that the solution interposed between the electrodes can be analyzed more strictly from the potential difference.
- the optical fibers can be exposed through different openings 77, 78, and the solution in the region where the light rays output from them can intersect can be accurately analyzed from a known distance.
- the lancet according to the second modification of the first to third embodiments will be described in detail below with reference to FIGS.
- the lancet of Modification 2 has the same configuration as the lancet 1 of Embodiment 1 except that the lancet further includes a plurality of vertical holes for accommodating the medicine and a sealing portion for sealing the vertical holes. Descriptions of overlapping points are omitted.
- the lancet 102 of the second modification extends in the Z direction for accommodating a medicine.
- a sealing portion 92 made of a biodegradable material for sealing the vertical holes 91a to 91d. After filling the vertical holes 91a-91d with microparticles or fluid (not shown) containing a drug, they are sealed with a sealing portion 92 so as not to deviate from the vertical holes 91a-91d.
- the sealing portion 92 is formed such that the thickness in the Z direction differs at the positions where the vertical holes 91a to 91d are arranged.
- the sealing portion 92 is configured to have an inclined thickness as shown in FIG. 15 (a) or to have a step as shown in FIG. 15 (b). In this way, it is possible to control the timing at which the drug contained in each of the vertical holes 91a and 91d is gradually released.
- the passage 71 of the lancet, the chamber 81, and the vertical hole 9 la-91d can freely output light such as an excimer laser as easily understood by those skilled in the art. It can be formed using a laser device which can be controlled at a high speed.
- the lancet 4 of the fourth embodiment will be described in detail below with reference to FIGS.
- the cross section when cut along an arbitrary cutting plane parallel to the YZ plane is triangular, whereas the cut surface of the lancet 4 of the fourth embodiment is substantially
- the lancet 1 has the same configuration as that of the lancet 1 of the first embodiment except that the lancet 1 has a trapezoidal shape.
- the lancet 4 of the fourth embodiment has an arbitrary cut surface parallel to the YZ plane.
- the base (top and bottom) of the trapezoidal cross section changes depending on the distance from the tip 11 or the position in the X direction, while its height is constant (H).
- the lancet 4 of the fourth embodiment includes first and second enlarged regions (cell incision regions) 10, 30 in which the base of the trapezoidal cross section cut along the cutting plane parallel to the YZ plane monotonically increases;
- the trapezoidal cross section has at least one reduction region (frictional force reduction region) 20 in which the bottom monotonically decreases.
- the holding section 40 is connected to the subsequent enlarged area. Connected to 20.
- the lancet 4 of the present invention is formed using the above-described biocompatible material, but is preferably integrally formed using a biodegradable material, so that the lancet 4 can be easily disposed of, and a part of the lancet 4 can be disposed. Can be moored inside the body.
- the bottom of the largest cross-section that gives the largest cross-sectional area in the first and second enlarged regions 10, 30 has substantially the same length.
- the height (H) of the trapezoidal cross section is as low as possible when dissecting cell tissue, and is preferably as low as possible (lancet 4 is thin), but as high as possible to have sufficient strength. It is preferable to use a razor (the lancet 4 is thicker). More preferably, the height) has a length that is at least about 1Z8 times the base of the largest cross section, ie, the second diagonal (L).
- the base of the minimum cross-section that gives the minimum cross-sectional area in the reduced area 20 is preferably about 1 / the base of the maximum cross-section. It is twice or more, more preferably about 2Z3 times or more.
- the distance (D) between the maximum cross sections in each of the enlarged regions 10 and 30 is preferably separated by at least about 1 zm.
- the additional reduced area and the enlarged area may be integrally formed following the second enlarged area 20.
- a constant region 60 in which a cross section cut along an arbitrary YZ plane gives a substantially constant cross-sectional area is integrated between the reduced region and the enlarged region. You can mold it.
- the length of the base is preferably set to the second enlarged area as shown in FIG. Designed to increase more slowly than 30. That is, the rate at which the length of the base of the first enlarged area 10 increases is preferably about 1/4 to about 1 times the rate at which the length of the base of the second enlarged area 30 increases. Is designed to be about 1/3 times larger.
- the lancet 4 of the fourth embodiment can enter the cell tissue more easily, and can reduce the pain given to the patient.
- Fig. 19 (a) is a perspective view similar to Fig. 3 (Lancet 1) and Fig. 10 (a) (Lancet 3).
- 19 (b)-(d) are a front view, a side view, and a plan view, respectively, similar to FIGS. 4 (a)-(c) (Lancet 1).
- the cross section taken along an arbitrary plane parallel to the YZ plane is triangular, whereas the cross section of the lancet 5 of the fifth embodiment has a semicircular shape. Except for this point, the lancet 1 has the same configuration as the lancet 1 of the first embodiment, and a description of the same points will be omitted.
- the lancet 5 of the present invention extends in a predetermined direction (X direction), and a cross section cut along a plane perpendicular thereto (a cross section cut along a Yz plane) is referred to in the present application.
- the cross-sectional area of the “vertical cross section” regularly increases and decreases depending on the distance from the tip 11.
- the lancet 5 has a plurality of maximum points 22a, 22b, 22c at which the cross-sectional area of the vertical cross section is maximum, and a plurality of minimum points 23a, 23b, 23c at which the cross-sectional area of the vertical cross section is minimum.
- the lancet 5 shown in FIG. 19 has a plurality of arbitrary maximum points and minimum points which are illustrated as having three maximum points and three minimum points, respectively.
- the cross-sectional area of the vertical cross section at the local maximum point 22a closest to the distal end portion 11 is the same as the cross-sectional area of the vertical cross section at each of the other local maximum points 22b and 22c. Is designed to be the same as the cross-sectional area of the vertical section at each of the other minimum points 23b and 23c.
- the distance D between a pair of adjacent maximum points for example, the distance between the maximum points 22a and 22b is substantially the same as the distance between the maximum points 22b and 22c. .
- the cross-sectional area of the vertical cross section is The distance between the local maximum point and the local minimum point, for example, between the local maximum point 22a and the local minimum point 23a, between the local minimum point 23a and the local maximum point 22b, linearly increases and decreases.
- the cross-sectional area of the vertical cross section may be between adjacent local maximum points and local minimum points, and may change in a curved manner.
- the tip 11 of the first enlarged region (cell incision region) 10 is removed. As a fulcrum, it intrudes into the cell tissue by pushing out the surrounding cell tissue. At this time, the frictional force generated between the first enlarged region 10 and the peripheral cells is extremely large, and the peripheral cells can be strongly drawn deeper by the frictional force with the penetration of the lancet 1 into the body.
- the lancet 5 of the present invention further advances into the body after the first enlarged region 10 enters the body, the cross-sectional area in the reduced region (frictional force relaxing region) 20 decreases.
- the second enlarged region 30 of the lancet 5 invades the body, it intrudes into the cell tissue by pushing and spreading the surrounding cell tissue.
- the cross-sectional area force S of the vertical cross section at the local maximum point 22a closest to the distal end portion 11 is designed to be the same as the cross-sectional area of the vertical cross section at each of the other local maximum points 22b and 22c. Therefore, in the enlarged area including the second enlarged area 30, it is possible to prevent the peripheral cells from being unnecessarily pushed and spread (stressing the peripheral cells) when entering the body.
- the angle ⁇ that intersects the axis is preferably larger than the angle ⁇ at which the slope of the second enlarged area 30 is tolerant of the X axis.
- the lancet 5 of the present invention has a semicircular vertical section when cut along any plane parallel to the ⁇ - ⁇ plane.
- the lancets 103, 104, 105, and 106 of the modified example 3-16 of the fifth embodiment have a vertical cross section that is not a semicircle when cut along any plane parallel to the ⁇ - ⁇ plane.
- the run of the fifth embodiment is identical except that it has a perfect circular shape, an elliptical shape, a rectangular shape, and a hexagonal shape. It has the same configuration as set 5.
- the lancets 103, 104, 105, and 106 of Modifications 3 to 6 have the same advantages as the lancet 5 of the fifth embodiment, substantially reduce the pain given to the patient, and reduce This makes it possible to minimize irreparable damage.
- FIG. 25 is a plan view similar to FIG. 4 (c) (Lancet 1) and FIG. 10 (c) (Lancet 3).
- the lancet 1 of the first embodiment the cross-sectional area of the vertical cross section at each local maximum point is all the same, whereas according to the lancet 6 of the sixth embodiment, the local maximum point 22a closest to the tip 11 is obtained.
- the cross-sectional area of the vertical cross-section is larger than the cross-sectional area of the vertical cross-section at the other local maximum points 22b, 22c, etc.
- the cross-sectional area of the vertical cross-section at each of the local maximum points 22a, 22b, 22c is from the front end 11 to the rear end 18
- the configuration is the same as that of the lancet 1 of the first embodiment except that it gradually decreases toward. Therefore, the description of the overlapping points will be omitted.
- the distance (Dl, D2, D3, D4, D5) between a pair of adjacent maximum points of the lancet 6 is (1) from the front end to the rear end.
- the lancet gradually becomes shorter (less than 0 , and the lancet shown in Fig. 25 shows the maximum cross section; 22a, 22b, 22c).
- the cross-sectional area of the vertical cross section at each of the minimum points 23a, 23b, 23c and 23d is constant.
- Embodiment 6 of the present invention since the cross-sectional area of the vertical cross section at each of the minimum points 23a, 23b, 23c, and 23d is constant, the rear end portion A safe lancet 6 that is hard to break at the minimum point 23d near 18 can be realized.
- the lancet according to the seventh modification of the sixth embodiment will be described below in detail with reference to FIG.
- the lancet 107 of the modified example 7 of the sixth embodiment is provided at each of the local maximum points 22a, 22b, and 22c. While the cross-sectional area of the vertical cross section is constant, the cross-sectional area of the vertical cross section at each of the minimum points 23a, 23b, 23c, and 23d gradually increases (in the -X direction) from the front end 11 to the rear end 18. It is configured to be large. That is, the vertical section force at the minimum point 23d closest to the rear end 18 is larger than the vertical sections at all other minimum points 23a, 23b, and 23c. Therefore, according to the modified example 7, it is possible to provide a safer lancet 107 that is harder to break at the minimum point 23d near the rear end portion 18 than the lancet 6 of the sixth embodiment.
- the cross-sectional area of the straight section at each local maximum point 22a, 22b, 22c is constant, and each local minimum point 23a, except the local minimum point 23d closest to the rear end portion 18,
- the cross-sectional areas of the vertical cross sections at 23b and 23c are also constant. That is, it is formed such that only the cross-sectional area of the vertical cross section at the minimum point 23d closest to the rear end portion 18 is smaller than the cross-sectional area of the vertical cross section at each of the other minimum points 23a, 23b, and 23c.
- the lancet 108 After puncturing the cell tissue, the lancet 108 thus configured can be intentionally broken at the minimum point 23d near the rear end 18, and a part of the lancet 108 can be left in the body. it can. However, when the lancet 108 is used as an indwelling needle, the lancet 108 needs to be integrally molded using a biodegradable material such as polylactic acid.
- the lancets 107 and 108 have the same effect as the lancet 6, and can substantially alleviate the pain given to the patient and minimize the irreparable damage to peripheral cells.
- Fig. 28 (a) is a bottom view when the lancet 1 shown in Fig. 3 is viewed in the Z direction (from below to above), and Fig. 28 (b) is a view when the lancet 1 is cut along the X-Z plane.
- FIG. The lancet 109 of Modification 9 has the diffraction grating 24 provided on the bottom surface 73.
- this diffraction grating 24 For example, it has a slope 26 inclined at an angle of 45 ° with the X-axis.
- the pitch P between the vertices 25 is made smaller than that of erythrocytes and the like. It is preferable to make it difficult to adhere to the top, for example, it is preferably in the range of 1 to 25 ⁇ m.
- the lancet 109 As described above, according to the lancet 109 according to the ninth modification, it is possible to instantaneously measure the content of a ketone body or the amount of blood glucose contained in blood using a laser measurement device (not shown).
- FIGS. 29 (a) and (b) are plan views similar to FIGS. 4 (c) and 10 (c), each including a tip 11 having a radius of curvature of 10 ⁇ m and 3 ⁇ m, respectively. 110 is shown.
- the lancet 110 according to Modification 10 has a radius of curvature of about 10 zm as shown in FIG. 29 (a), and more preferably, as shown in FIG. 29 (b). 3 xm radius of curvature (R)
- the lancet 110 according to the tenth modification has many maximum points 22 and minimum points 23 of the lancet 110, and a pair of adjacent maximum points
- the maximum point 22 or the minimum point 23 can be used as a certain size gauge when punctured into the cell tissue. Alternatively, marking or coloring may be performed at a predetermined distance from the tip 11 so that the distance from the tip 11 can be easily indicated.
- FIGS. 30 (a)-(c) are a front view, a side view, and a plan view similar to FIGS. 4 (a)-(c), respectively, showing a pair of lancets la, lb according to the first embodiment shown in FIG. Are held together in a holding section 40, and a slit 31 is formed between a pair of lancets la and lb.
- FIGS. 31 (a)-(c) are front, side and plan views similar to FIGS. 19 (b)-(d), respectively, showing a pair of lancets according to the fifth embodiment shown in FIG. It has a structure in which 5a and 5b are bonded to each other at a holding portion 40, and a slit 31 is formed between a pair of lancets 5a and 5b.
- the lancets 111 and 112 according to the modified examples 11 and 12 have the slit 31 between a pair of lancets, and can expect the same advantages as the lancets 1 and 5.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT04807140T ATE497726T1 (de) | 2003-12-19 | 2004-12-16 | Medizinisches nadel und medizinprodukt |
US10/524,487 US7740621B2 (en) | 2003-12-19 | 2004-12-16 | Medical needle and medical device |
DE602004031361T DE602004031361D1 (de) | 2003-12-19 | 2004-12-16 | Medizinisches nadel und medizinprodukt |
KR1020067011941A KR101149852B1 (ko) | 2003-12-19 | 2004-12-16 | 의료용 바늘 및 의료용 디바이스 |
EP04807140A EP1695664B1 (en) | 2003-12-19 | 2004-12-16 | Medical needle and medical device |
JP2005516328A JP3887657B2 (ja) | 2003-12-19 | 2004-12-16 | 医療用針および医療用デバイス |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003422999 | 2003-12-19 | ||
JP2003-422999 | 2003-12-19 | ||
US10/784877 | 2004-02-24 | ||
US10/784,877 US7361182B2 (en) | 2003-12-19 | 2004-02-24 | Medical lancet |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005058162A1 true WO2005058162A1 (ja) | 2005-06-30 |
Family
ID=34703302
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/018781 WO2005058162A1 (ja) | 2003-12-19 | 2004-12-16 | 医療用針および医療用デバイス |
Country Status (8)
Country | Link |
---|---|
US (2) | US7361182B2 (ja) |
EP (1) | EP1695664B1 (ja) |
JP (6) | JP3887657B2 (ja) |
KR (1) | KR101149852B1 (ja) |
CN (2) | CN101254107B (ja) |
AT (1) | ATE497726T1 (ja) |
DE (1) | DE602004031361D1 (ja) |
WO (1) | WO2005058162A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005334369A (ja) * | 2004-05-27 | 2005-12-08 | Terumo Corp | 穿刺針および穿刺具 |
WO2007080435A1 (en) * | 2006-01-09 | 2007-07-19 | Michael Solomakakis | Mosquito needle comprising carbon nanotubes |
EP1844763A1 (en) | 2005-01-31 | 2007-10-17 | BioSerenTach Co., Ltd. | Percutaneously absorbable preparation, percutaneously absorbable preparation holding sheet, and percutaneously absorbable preparation holding equipment |
JP2007333540A (ja) * | 2006-06-14 | 2007-12-27 | Sumitomo Electric Ind Ltd | バイオセンサチップおよびその製造方法 |
CN100457210C (zh) * | 2005-11-18 | 2009-02-04 | 吉林大学 | 无痛注射器 |
JP2010099501A (ja) * | 2003-12-19 | 2010-05-06 | Lightnix Inc | 医療用針および医療用デバイス |
JP2012245028A (ja) * | 2011-05-25 | 2012-12-13 | Kansai Univ | 穿刺ユニット |
JP2013233240A (ja) * | 2012-05-08 | 2013-11-21 | Koden Kogyo Kk | 穿刺針、微量体液採取用冶具および微量薬液投与用冶具 |
WO2018221536A1 (ja) * | 2017-05-29 | 2018-12-06 | 株式会社アルチザンラボ | 穿刺針 |
WO2021251478A1 (ja) * | 2020-06-11 | 2021-12-16 | 国立大学法人東北大学 | 振動針装置及び針の挿入方法 |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6036924A (en) | 1997-12-04 | 2000-03-14 | Hewlett-Packard Company | Cassette of lancet cartridges for sampling blood |
US6391005B1 (en) | 1998-03-30 | 2002-05-21 | Agilent Technologies, Inc. | Apparatus and method for penetration with shaft having a sensor for sensing penetration depth |
US8641644B2 (en) | 2000-11-21 | 2014-02-04 | Sanofi-Aventis Deutschland Gmbh | Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means |
WO2002100254A2 (en) | 2001-06-12 | 2002-12-19 | Pelikan Technologies, Inc. | Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge |
ES2352998T3 (es) | 2001-06-12 | 2011-02-24 | Pelikan Technologies Inc. | Accionador eléctrico de lanceta. |
US8337419B2 (en) | 2002-04-19 | 2012-12-25 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US9226699B2 (en) | 2002-04-19 | 2016-01-05 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling module with a continuous compression tissue interface surface |
US9795747B2 (en) | 2010-06-02 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Methods and apparatus for lancet actuation |
US7025774B2 (en) | 2001-06-12 | 2006-04-11 | Pelikan Technologies, Inc. | Tissue penetration device |
CA2448902C (en) | 2001-06-12 | 2010-09-07 | Pelikan Technologies, Inc. | Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties |
US7981056B2 (en) | 2002-04-19 | 2011-07-19 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
CA2448905C (en) | 2001-06-12 | 2010-09-07 | Pelikan Technologies, Inc. | Blood sampling apparatus and method |
AU2002344825A1 (en) | 2001-06-12 | 2002-12-23 | Pelikan Technologies, Inc. | Method and apparatus for improving success rate of blood yield from a fingerstick |
US9427532B2 (en) | 2001-06-12 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7175642B2 (en) | 2002-04-19 | 2007-02-13 | Pelikan Technologies, Inc. | Methods and apparatus for lancet actuation |
US7232451B2 (en) | 2002-04-19 | 2007-06-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8579831B2 (en) | 2002-04-19 | 2013-11-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7648468B2 (en) | 2002-04-19 | 2010-01-19 | Pelikon Technologies, Inc. | Method and apparatus for penetrating tissue |
US8360992B2 (en) | 2002-04-19 | 2013-01-29 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US9248267B2 (en) | 2002-04-19 | 2016-02-02 | Sanofi-Aventis Deustchland Gmbh | Tissue penetration device |
US7909778B2 (en) | 2002-04-19 | 2011-03-22 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8702624B2 (en) | 2006-09-29 | 2014-04-22 | Sanofi-Aventis Deutschland Gmbh | Analyte measurement device with a single shot actuator |
US8372016B2 (en) | 2002-04-19 | 2013-02-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling and analyte sensing |
US9314194B2 (en) | 2002-04-19 | 2016-04-19 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
US7229458B2 (en) | 2002-04-19 | 2007-06-12 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7291117B2 (en) | 2002-04-19 | 2007-11-06 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7717863B2 (en) | 2002-04-19 | 2010-05-18 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8784335B2 (en) | 2002-04-19 | 2014-07-22 | Sanofi-Aventis Deutschland Gmbh | Body fluid sampling device with a capacitive sensor |
US7297122B2 (en) | 2002-04-19 | 2007-11-20 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7547287B2 (en) | 2002-04-19 | 2009-06-16 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US8267870B2 (en) | 2002-04-19 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for body fluid sampling with hybrid actuation |
US7491178B2 (en) * | 2002-04-19 | 2009-02-17 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US9795334B2 (en) | 2002-04-19 | 2017-10-24 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US7371247B2 (en) | 2002-04-19 | 2008-05-13 | Pelikan Technologies, Inc | Method and apparatus for penetrating tissue |
US7331931B2 (en) | 2002-04-19 | 2008-02-19 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7901362B2 (en) | 2002-04-19 | 2011-03-08 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7713214B2 (en) | 2002-04-19 | 2010-05-11 | Pelikan Technologies, Inc. | Method and apparatus for a multi-use body fluid sampling device with optical analyte sensing |
US7674232B2 (en) | 2002-04-19 | 2010-03-09 | Pelikan Technologies, Inc. | Method and apparatus for penetrating tissue |
US7976476B2 (en) | 2002-04-19 | 2011-07-12 | Pelikan Technologies, Inc. | Device and method for variable speed lancet |
US7892183B2 (en) | 2002-04-19 | 2011-02-22 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
US8221334B2 (en) | 2002-04-19 | 2012-07-17 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for penetrating tissue |
US8574895B2 (en) | 2002-12-30 | 2013-11-05 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus using optical techniques to measure analyte levels |
EP2238892A3 (en) | 2003-05-30 | 2011-02-09 | Pelikan Technologies Inc. | Apparatus for body fluid sampling |
US7850621B2 (en) | 2003-06-06 | 2010-12-14 | Pelikan Technologies, Inc. | Method and apparatus for body fluid sampling and analyte sensing |
WO2006001797A1 (en) | 2004-06-14 | 2006-01-05 | Pelikan Technologies, Inc. | Low pain penetrating |
WO2005033659A2 (en) | 2003-09-29 | 2005-04-14 | Pelikan Technologies, Inc. | Method and apparatus for an improved sample capture device |
WO2005037095A1 (en) | 2003-10-14 | 2005-04-28 | Pelikan Technologies, Inc. | Method and apparatus for a variable user interface |
US7822454B1 (en) | 2005-01-03 | 2010-10-26 | Pelikan Technologies, Inc. | Fluid sampling device with improved analyte detecting member configuration |
US8668656B2 (en) | 2003-12-31 | 2014-03-11 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for improving fluidic flow and sample capture |
US7819822B2 (en) * | 2004-03-06 | 2010-10-26 | Roche Diagnostics Operations, Inc. | Body fluid sampling device |
DK1722670T3 (da) | 2004-03-06 | 2014-01-06 | Hoffmann La Roche | Kropsfluidum-prøveudtagningsapparat |
US7909776B2 (en) * | 2004-04-30 | 2011-03-22 | Roche Diagnostics Operations, Inc. | Lancets for bodily fluid sampling supplied on a tape |
US8591436B2 (en) * | 2004-04-30 | 2013-11-26 | Roche Diagnostics Operations, Inc. | Lancets for bodily fluid sampling supplied on a tape |
EP1751546A2 (en) | 2004-05-20 | 2007-02-14 | Albatros Technologies GmbH & Co. KG | Printable hydrogel for biosensors |
WO2005120365A1 (en) | 2004-06-03 | 2005-12-22 | Pelikan Technologies, Inc. | Method and apparatus for a fluid sampling device |
US9775553B2 (en) | 2004-06-03 | 2017-10-03 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for a fluid sampling device |
US20060030788A1 (en) * | 2004-08-04 | 2006-02-09 | Daniel Wong | Apparatus and method for extracting bodily fluid utilizing a flat lancet |
US8652831B2 (en) | 2004-12-30 | 2014-02-18 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte measurement test time |
CN100415312C (zh) * | 2005-06-20 | 2008-09-03 | 王月安 | 一次性注射器或输液器针头 |
US8057404B2 (en) * | 2005-10-12 | 2011-11-15 | Panasonic Corporation | Blood sensor, blood testing apparatus, and method for controlling blood testing apparatus |
US20090093735A1 (en) * | 2006-03-29 | 2009-04-09 | Stephan Korner | Test unit and test system for analyzing body fluids |
US20080281292A1 (en) * | 2006-10-16 | 2008-11-13 | Hickingbotham Dyson W | Retractable Injection Port |
CN104069567A (zh) * | 2007-03-19 | 2014-10-01 | 茵苏莱恩医药有限公司 | 药物输送设备 |
US8622991B2 (en) | 2007-03-19 | 2014-01-07 | Insuline Medical Ltd. | Method and device for drug delivery |
JP4992030B2 (ja) * | 2007-06-12 | 2012-08-08 | 株式会社パイロットコーポレーション | 生体用針体 |
US20090030381A1 (en) * | 2007-07-23 | 2009-01-29 | Lind Casey J | Arced Hypodermic Needle |
KR100915838B1 (ko) * | 2007-07-30 | 2009-09-07 | 김윤성 | 주사기의 바늘구조 |
JP5044334B2 (ja) * | 2007-09-06 | 2012-10-10 | 株式会社ニコン | 採液収容装置 |
US9186097B2 (en) * | 2007-09-17 | 2015-11-17 | Roche Diabetes Care, Inc. | Body fluid lancing, acquiring, and testing cartridge design |
US8961431B2 (en) * | 2009-09-28 | 2015-02-24 | Roche Diagnostics Operations, Inc. | Body fluid lancing, acquiring, and testing cartridge design |
US20090177114A1 (en) * | 2007-12-13 | 2009-07-09 | Yem Chin | Echogenic needle aspiration device |
EP2231229A1 (en) | 2007-12-18 | 2010-09-29 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
US9386944B2 (en) | 2008-04-11 | 2016-07-12 | Sanofi-Aventis Deutschland Gmbh | Method and apparatus for analyte detecting device |
EP2316339A4 (en) | 2008-08-01 | 2012-10-24 | Lightnix Inc | SENSOR WITH A PRECIOUS NEEDLE WITH A DUCTED CHANNEL |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
CN102196836B (zh) * | 2008-10-25 | 2013-12-18 | 金允圣 | 注射器的针结构 |
US20100114677A1 (en) * | 2008-11-06 | 2010-05-06 | Mark Carlson | System including automated teller machine with data bearing medium |
MX2011004817A (es) | 2008-11-07 | 2011-07-28 | Insuline Medical Ltd | Dispositivo y metodo para suministrar farmacos. |
US9375169B2 (en) | 2009-01-30 | 2016-06-28 | Sanofi-Aventis Deutschland Gmbh | Cam drive for managing disposable penetrating member actions with a single motor and motor and control system |
WO2012018486A2 (en) * | 2010-07-26 | 2012-02-09 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
WO2010101620A2 (en) | 2009-03-02 | 2010-09-10 | Seventh Sense Biosystems, Inc. | Systems and methods for creating and using suction blisters or other pooled regions of fluid within the skin |
US8827971B2 (en) | 2011-04-29 | 2014-09-09 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving fluids |
JP5748394B2 (ja) * | 2009-03-30 | 2015-07-15 | 凸版印刷株式会社 | 針状体製造方法および針状体 |
US9265454B2 (en) | 2010-03-30 | 2016-02-23 | Terumo Kabushiki Kaisha | Puncture needle and puncture device |
US8965476B2 (en) | 2010-04-16 | 2015-02-24 | Sanofi-Aventis Deutschland Gmbh | Tissue penetration device |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
JP2012139407A (ja) * | 2010-12-29 | 2012-07-26 | Terumo Corp | 穿刺体 |
WO2012149155A1 (en) | 2011-04-29 | 2012-11-01 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
CA2833175A1 (en) | 2011-04-29 | 2012-11-01 | Seventh Sense Biosystems, Inc. | Devices and methods for collection and/or manipulation of blood spots or other bodily fluids |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
AU2013219321B2 (en) * | 2012-02-17 | 2017-07-20 | Cosmed Pharmaceutical Co., Ltd. | Microneedle of short-time dissolution type |
US9615973B1 (en) * | 2012-05-13 | 2017-04-11 | Surgical Specialties Corporation | Surgical knife |
US9237905B2 (en) * | 2012-11-28 | 2016-01-19 | Ronald M. Chase | Medical instrument for insertion into a body region of a subject |
CN103211601B (zh) * | 2013-04-09 | 2014-12-10 | 苏州市玮琪生物科技有限公司 | 一种采血针 |
JP6332786B2 (ja) | 2014-02-14 | 2018-05-30 | 株式会社ライトニックス | 医療用針および穿刺具 |
IL231751A (en) | 2014-03-27 | 2016-08-31 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Medical device for tissue removal |
WO2015200923A2 (en) * | 2014-06-27 | 2015-12-30 | The Trustees Of Columbia University In The City Of New York | Apparatus for perforation and aspiration of inner ear |
KR101906590B1 (ko) * | 2016-01-14 | 2018-10-11 | 한국전자통신연구원 | 니들 구조체 및 그를 구비하는 생체 신호 측정 장치 |
IL251684B (en) | 2017-04-09 | 2019-01-31 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Device and method for creating a canal in soft tissue |
CN110478569B (zh) * | 2019-08-16 | 2021-07-16 | 吉林大学 | 一种防脱针仿生减痛静脉注射针头 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3492992A (en) | 1969-03-26 | 1970-02-03 | Deknatel Inc | Hypodermic needle |
JPS5368594U (ja) * | 1976-11-13 | 1978-06-08 | ||
JPS6063040A (ja) * | 1983-09-15 | 1985-04-11 | ベクトン・デイツキンソン・アンド・カンパニ− | 血液ランセツト組立て体 |
JPS6131167A (ja) * | 1984-07-24 | 1986-02-13 | 西郷 諭美 | 周面に注出孔を有する注射針 |
JPH1057490A (ja) | 1996-06-20 | 1998-03-03 | Becton Dickinson & Co | 多斜角面の先端を有する針及びその製造方法 |
JP2002045423A (ja) * | 2000-08-01 | 2002-02-12 | Doctor Japan Kk | 穿刺針 |
WO2002100273A1 (fr) * | 2001-06-07 | 2002-12-19 | Arkray, Inc. | Dispositif d'ejection |
JP2003116821A (ja) * | 2001-08-06 | 2003-04-22 | Lifescan Inc | 生理学的サンプル収集装置および当該装置を使用する方法 |
EP1346686A2 (en) | 2002-03-05 | 2003-09-24 | Bayer Healthcare, LLC | Fluid collection apparatus having an integrated lancet and reaction area |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5368594A (en) | 1976-11-30 | 1978-06-19 | Mitsubishi Electric Corp | Radar receiver protector |
US4924865A (en) * | 1986-05-20 | 1990-05-15 | Concept, Inc. | Repair tack for bodily tissue |
US5250066A (en) | 1990-03-19 | 1993-10-05 | Becton Dickinson And Company | Plastic pointed articles and method for their preparation |
ES2085441T3 (es) * | 1990-12-13 | 1996-06-01 | Cook Inc | Aguja intraosea. |
US5542920A (en) * | 1994-09-12 | 1996-08-06 | Delab | Needle-less parenteral introduction device |
US5766163A (en) * | 1996-07-03 | 1998-06-16 | Eclipse Surgical Technologies, Inc. | Controllable trocar for transmyocardial revascularization (TMR) via endocardium method and apparatus |
US5928207A (en) | 1997-06-30 | 1999-07-27 | The Regents Of The University Of California | Microneedle with isotropically etched tip, and method of fabricating such a device |
US6692499B2 (en) * | 1997-07-02 | 2004-02-17 | Linvatec Biomaterials Oy | Surgical fastener for tissue treatment |
US6183444B1 (en) * | 1998-05-16 | 2001-02-06 | Microheart, Inc. | Drug delivery module |
US6139562A (en) * | 1998-03-30 | 2000-10-31 | Agilent Technologies, Inc. | Apparatus and method for incising |
WO1999049792A1 (en) * | 1998-04-01 | 1999-10-07 | Bionx Implants Oy | Bioabsorbable surgical fastener for tissue treatment |
US6146387A (en) * | 1998-08-26 | 2000-11-14 | Linvatec Corporation | Cannulated tissue anchor system |
US7211088B2 (en) * | 1999-02-02 | 2007-05-01 | Arthrex, Inc. | Bioabsorbable tissue tack with oval-shaped head and method of tissue fixation using the same |
US6623492B1 (en) * | 2000-01-25 | 2003-09-23 | Smith & Nephew, Inc. | Tissue fastener |
GB0017999D0 (en) * | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
WO2002064193A2 (en) | 2000-12-14 | 2002-08-22 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
US7445616B2 (en) * | 2001-03-23 | 2008-11-04 | Petrakis Dennis N | Temperature responsive systems |
US6673058B2 (en) * | 2001-06-20 | 2004-01-06 | Scimed Life Systems, Inc. | Temporary dilating tip for gastro-intestinal tubes |
US6554809B2 (en) * | 2001-08-02 | 2003-04-29 | Teodulo Aves | Epidural catheter needle |
US20040249394A1 (en) * | 2001-08-06 | 2004-12-09 | Arthrex, Inc. | Compact suture punch with malleable needle |
JP2003116962A (ja) | 2001-10-11 | 2003-04-22 | Seirin Kk | 鍼灸針 |
US7429258B2 (en) | 2001-10-26 | 2008-09-30 | Massachusetts Institute Of Technology | Microneedle transport device |
US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
JP4026745B2 (ja) | 2002-03-26 | 2007-12-26 | 財団法人大阪産業振興機構 | 医療用システムおよびその製造方法 |
US7361182B2 (en) * | 2003-12-19 | 2008-04-22 | Lightnix, Inc. | Medical lancet |
US7645268B2 (en) * | 2004-03-25 | 2010-01-12 | Boston Scientific Scimed, Inc. | Needles and methods of using same |
US7850656B2 (en) * | 2005-04-29 | 2010-12-14 | Warsaw Orthopedic, Inc. | Devices and methods for delivering medical agents |
-
2004
- 2004-02-24 US US10/784,877 patent/US7361182B2/en active Active
- 2004-12-16 JP JP2005516328A patent/JP3887657B2/ja active Active
- 2004-12-16 WO PCT/JP2004/018781 patent/WO2005058162A1/ja not_active Application Discontinuation
- 2004-12-16 CN CN2008100817271A patent/CN101254107B/zh active Active
- 2004-12-16 US US10/524,487 patent/US7740621B2/en active Active
- 2004-12-16 KR KR1020067011941A patent/KR101149852B1/ko active IP Right Grant
- 2004-12-16 EP EP04807140A patent/EP1695664B1/en active Active
- 2004-12-16 DE DE602004031361T patent/DE602004031361D1/de active Active
- 2004-12-16 AT AT04807140T patent/ATE497726T1/de not_active IP Right Cessation
- 2004-12-16 CN CNB2004800345209A patent/CN100475141C/zh not_active Expired - Fee Related
-
2006
- 2006-07-21 JP JP2006199498A patent/JP2006297142A/ja active Pending
- 2006-07-21 JP JP2006199497A patent/JP4065906B2/ja active Active
- 2006-07-21 JP JP2006199496A patent/JP4649565B2/ja active Active
- 2006-07-21 JP JP2006199495A patent/JP2006297141A/ja active Pending
-
2010
- 2010-01-08 JP JP2010003029A patent/JP5061284B2/ja active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3492992A (en) | 1969-03-26 | 1970-02-03 | Deknatel Inc | Hypodermic needle |
JPS5368594U (ja) * | 1976-11-13 | 1978-06-08 | ||
JPS6063040A (ja) * | 1983-09-15 | 1985-04-11 | ベクトン・デイツキンソン・アンド・カンパニ− | 血液ランセツト組立て体 |
JPS6131167A (ja) * | 1984-07-24 | 1986-02-13 | 西郷 諭美 | 周面に注出孔を有する注射針 |
JPH1057490A (ja) | 1996-06-20 | 1998-03-03 | Becton Dickinson & Co | 多斜角面の先端を有する針及びその製造方法 |
JP2002045423A (ja) * | 2000-08-01 | 2002-02-12 | Doctor Japan Kk | 穿刺針 |
WO2002100273A1 (fr) * | 2001-06-07 | 2002-12-19 | Arkray, Inc. | Dispositif d'ejection |
JP2003116821A (ja) * | 2001-08-06 | 2003-04-22 | Lifescan Inc | 生理学的サンプル収集装置および当該装置を使用する方法 |
EP1346686A2 (en) | 2002-03-05 | 2003-09-24 | Bayer Healthcare, LLC | Fluid collection apparatus having an integrated lancet and reaction area |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010099501A (ja) * | 2003-12-19 | 2010-05-06 | Lightnix Inc | 医療用針および医療用デバイス |
JP2005334369A (ja) * | 2004-05-27 | 2005-12-08 | Terumo Corp | 穿刺針および穿刺具 |
JP4491280B2 (ja) * | 2004-05-27 | 2010-06-30 | テルモ株式会社 | 穿刺針および穿刺具 |
EP1844763B1 (en) | 2005-01-31 | 2018-08-08 | BioSerenTach Co., Ltd. | Percutaneously absorbable preparation, percutaneously absorbable preparation holding sheet, and percutaneously absorbable preparation holding equipment |
EP1844763A1 (en) | 2005-01-31 | 2007-10-17 | BioSerenTach Co., Ltd. | Percutaneously absorbable preparation, percutaneously absorbable preparation holding sheet, and percutaneously absorbable preparation holding equipment |
JP4913030B2 (ja) | 2005-01-31 | 2012-04-11 | 株式会社バイオセレンタック | 経皮吸収製剤、経皮吸収製剤保持シート、及び経皮吸収製剤保持用具 |
CN100457210C (zh) * | 2005-11-18 | 2009-02-04 | 吉林大学 | 无痛注射器 |
WO2007080435A1 (en) * | 2006-01-09 | 2007-07-19 | Michael Solomakakis | Mosquito needle comprising carbon nanotubes |
JP2007333540A (ja) * | 2006-06-14 | 2007-12-27 | Sumitomo Electric Ind Ltd | バイオセンサチップおよびその製造方法 |
JP2012245028A (ja) * | 2011-05-25 | 2012-12-13 | Kansai Univ | 穿刺ユニット |
JP2013233240A (ja) * | 2012-05-08 | 2013-11-21 | Koden Kogyo Kk | 穿刺針、微量体液採取用冶具および微量薬液投与用冶具 |
WO2018221536A1 (ja) * | 2017-05-29 | 2018-12-06 | 株式会社アルチザンラボ | 穿刺針 |
WO2021251478A1 (ja) * | 2020-06-11 | 2021-12-16 | 国立大学法人東北大学 | 振動針装置及び針の挿入方法 |
Also Published As
Publication number | Publication date |
---|---|
ATE497726T1 (de) | 2011-02-15 |
JP2006334420A (ja) | 2006-12-14 |
KR20060111580A (ko) | 2006-10-27 |
DE602004031361D1 (de) | 2011-03-24 |
CN101254107B (zh) | 2011-05-18 |
KR101149852B1 (ko) | 2012-05-25 |
US7740621B2 (en) | 2010-06-22 |
JP3887657B2 (ja) | 2007-02-28 |
EP1695664A1 (en) | 2006-08-30 |
CN1882282A (zh) | 2006-12-20 |
JP2006297141A (ja) | 2006-11-02 |
JP5061284B2 (ja) | 2012-10-31 |
CN101254107A (zh) | 2008-09-03 |
JP2006297142A (ja) | 2006-11-02 |
JP2010099501A (ja) | 2010-05-06 |
JP4649565B2 (ja) | 2011-03-09 |
EP1695664A4 (en) | 2008-03-26 |
US20050149088A1 (en) | 2005-07-07 |
EP1695664B1 (en) | 2011-02-09 |
JPWO2005058162A1 (ja) | 2007-07-12 |
US7361182B2 (en) | 2008-04-22 |
JP4065906B2 (ja) | 2008-03-26 |
US20060100654A1 (en) | 2006-05-11 |
JP2006334419A (ja) | 2006-12-14 |
CN100475141C (zh) | 2009-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005058162A1 (ja) | 医療用針および医療用デバイス | |
US20090240165A1 (en) | Apparatus for containing sampled liquid | |
US6749575B2 (en) | Method for transdermal nucleic acid sampling | |
EP2545955B1 (en) | Medical needle and puncturing instrument | |
US20090036795A1 (en) | Substance sampling and/or substance delivery via skin | |
McAlister et al. | Microneedles for drug delivery and monitoring | |
JP6332786B2 (ja) | 医療用針および穿刺具 | |
MXPA03001694A (es) | Metodo para toma de muestra transdermal de acido nucleico. | |
AU2001283469A1 (en) | Method for transdermal nucleic acid sampling | |
JP2007061384A (ja) | 体液採取用具 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480034520.9 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2005524487 Country of ref document: US Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005516328 Country of ref document: JP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006100654 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10524487 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004807140 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2907/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067011941 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2004807140 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067011941 Country of ref document: KR |